



Transparency notification BlackRock, Inc.

Brussels (Belgium), 24 August 2018 – 20:00 (CEST) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 23 August 2018.

BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights and equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has decreased and has crossed downwards the 5% threshold on 22 August 2018.

On 22 August 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 051 239 UCB shares with voting rights (versus 9 149 508 shares in its previous notification), representing 4.65% of the total number of shares issued by the company (194 505 658) (versus 4.70% in its previous notification) as well as 639 374 equivalent financial instruments (versus 615 324 in its previous notification) representing 0.33% of the total number of shares issued by the company (versus 0.32% in its previous notification).

2. Content of the notification

The transparency notification dated 23 August 2018 includes the following information:

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
BlackRock, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Asset Management Deutschland AG	Max-Joseph-Straße 6, Munich, 80333, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock International Limited	Exchange Place One, 1 Seple Street, Edinburgh, EH3 8BL, U.K.
BlackRock Investment Management (Australia) Limited	Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan

- **Date on which the threshold is crossed:** 22 August 2018.
- **Threshold crossed (in %):** 5%
- **Denominator:** 194 505 658.
- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
BlackRock, Inc.	0	0		0,00%	
BlackRock (Netherlands) B.V.	20.988	20.988		0,01%	
BlackRock (Singapore) Limited	7.282	7.282		0,00%	
BlackRock Advisors (UK) Limited	1.487.630	1.526.019		0,78%	
BlackRock Advisors, LLC	222.173	217.837		0,11%	
BlackRock Asset Management Canada Limited	151.157	151.360		0,08%	
BlackRock Asset Management Deutschland AG	251.301	251.742		0,13%	
BlackRock Asset Management North Asia Limited	1.043	997		0,00%	
BlackRock Financial Management, Inc.	184.859	168.859		0,09%	
BlackRock Fund Advisors	2.405.460	2.381.014		1,22%	
BlackRock Institutional Trust Company, National Association	3.234.142	3.203.133		1,65%	
BlackRock International Limited	24.746	25.611		0,01%	
BlackRock Investment Management (Australia) Limited	69.580	72.837		0,04%	
BlackRock Investment Management (UK) Limited	409.124	351.166		0,18%	
BlackRock Investment Management, LLC	298.501	296.765		0,15%	
BlackRock Japan Co., Ltd.	381.522	375.629		0,19%	
Subtotal	9.149.508	9.051.239		4,65%	
TOTAL		9.051.239	0	4,65%	0,00%

B) Equivalent financial instruments	After the transaction					
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights
BlackRock Advisors (UK) Limited	Securities Lent			38.083	0,02%	physical
BlackRock Advisors (UK) Limited	Contract for Difference			4.027	0,00%	cash
BlackRock Advisors, LLC	Contract for Difference			15.682	0,01%	cash
BlackRock Institutional Trust Company, National Association	Contract for Difference			336.584	0,17%	cash
BlackRock Investment Management (UK) Limited	Contract for Difference			126.340	0,06%	cash
BlackRock Investment Management, LLC	Contract for Difference			118.658	0,06%	cash
TOTAL				639.374	0,33%	

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	9.690.613	4,98%

- **Chain of controlled undertakings through which the holding is effectively held:**

Please see the full chain of control in the 'Chain of Control' tab.

- **Additional information:**

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going below 5%.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news